SARS-COV-2 TESTING

HOLOGIC®

TRIFECTA

Introducing Hologic's SARS-CoV-2 testing TRIFECTA which offers simplified, sensitive, and scalable solutions for your lab.

Simplified Workflow

Expedite testing with a collection device that loads directly on the Panther® system, eliminating manual transfer steps, reducing labor, costs, and risks.

Superior Sensitivity[1]

Detect with the Aptima® SARS-CoV-2 assay* which provides superior sensitivity and serves a broad patient population with clinical, epidemiological, asymptomatic, and pooling claims.

Scalable Automation

Leverage the power of the Panther® system to consolidate SARS-CoV-2 testing with a broad range of STI, women's health and viral load assays on a fully automated high-throughput instrument.

From patient collection to results – trust Hologic as your long-term partner in SARS-CoV-2 testing and beyond.

LEARN MORE

* The Aptima® SARS-CoV-2 assay: This test has not been FDA cleared or approved; This test has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Reference: 1. Compared with other high-throughput, fully automated systems. U.S. Food and Drug Administration. SARS-CoV-2 Reference Panel Comparative Data. Last reviewed December 07, 2020. Accessed March 2, 2021. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data